Biocure Technology Inc.
CUREX
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -75.59% | -80.20% | -76.13% | -70.32% | 55.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -75.59% | -80.20% | -76.13% | -70.32% | 55.99% |
| Operating Income | 75.59% | 80.20% | 76.13% | 70.32% | -55.99% |
| Income Before Tax | 93.12% | 94.20% | 82.99% | 82.45% | -263.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 93.12% | 94.20% | 82.99% | 82.45% | -263.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 95.70% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -91.86% |
| Net Income | 93.18% | 94.24% | 84.00% | 85.61% | -346.70% |
| EBIT | 75.59% | 80.20% | 76.13% | 70.32% | -55.99% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 95.19% | 95.91% | 91.31% | 91.43% | -391.75% |
| Normalized Basic EPS | 78.34% | 82.87% | 83.91% | 82.80% | -82.80% |
| EPS Diluted | 95.19% | 95.91% | 91.31% | 91.43% | -391.75% |
| Normalized Diluted EPS | 78.34% | 82.87% | 83.91% | 82.80% | -82.80% |
| Average Basic Shares Outstanding | -54.16% | 191.46% | 182.56% | 171.50% | 146.44% |
| Average Diluted Shares Outstanding | -54.16% | 191.46% | 182.56% | 171.50% | 146.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |